ICML 2017 | Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma
Christian Buske, MD from the University Hospital Ulm, Ulm, Germany discusses the Phase III trial comparing the efficacy and safety of the biosimilar CT-P10 to rituximab in combination with CVP in advanced follicular lymphoma (NCT02162771). The rationale of the study was to establish if the biosimilar is indeed similar to the originator. Prof. Buske further discusses the potential of using the biosimilar in diffuse large B-cell lymphoma (DLBCL) based on extrapolation.
Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
Get great new content delivered to your inboxSign up